Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
Strausz, J., Rolski, J., Aziz, Z., Guckert, M. E., Wright, O., Bandekar, R. R., Thorn, S., Wissel, P., Herrstedt, J.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)
Grunberg, S. M., Aziz, Z., Shaharyar, A., Herrstedt, J., Roila, F., VanBelle, S., Bandekar, R. R., Guckert, M. E., Russo, M. W., Arpornwirat, W.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
Herrstedt, J., Grunberg, S., Rolski, J., Bandekar, R. R., Guckert, M. E., Camlett, I., Russo, M. W., Strausz, J., Aziz, Z., Thorn, S.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article